Davis Blaine
Known title: Chief Financial OfficerCIK: 0001802188
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Protara Completes THRIVE-3 Trial Enrollment. Protara Therapeutics has finished enrolling patients in the Phase 2b dose confirmation phase of its THRIVE-3 registrational trial for IV Choline Chloride. This milestone marks a significant step in the development process for the company's lead product. The stock is currently trading near its 52-week low, reflecting the ongoing uncertainty surrounding the upcoming trial results.
Transaction History
| RNAC | ▼ Sell | Open Market | 10,591 | $72K | 1/6/2026 | View on chart |
| RNAC | ▲ Buy | Grant | 37,000 | $0 | 1/2/2026 | View on chart |
| RNAC | ▼ Sell | Open Market | 4,028 | $68K | 1/6/2025 | View on chart |
| RNAC | ▼ Sell | Open Market | 3,961 | $66K | 1/3/2025 | View on chart |
| RNAC | ▲ Buy | Grant | 22,000 | $0 | 1/2/2025 | View on chart |
| RNAC | ▲ Buy | Grant | 2,424,000 | $0 | 1/2/2024 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 5,081 | $16K | 7/15/2022 | View on chart |
| TARA | ▲ Buy | Grant | 14,100 | $0 | 1/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
RNAC Presents New Retreatment Data for Descartes-08 at MGFA Session
Cartesian Therapeutics shared additional retreatment data for its lead candidate Descartes-08 in patients with generalized myasthenia gravis. The results were presented at the MGFA scientific session of the 2026 AANEM annual meeting. This update adds to the company's clinical development information and may influence future regulatory discussions.
RNAC Presents New Retreatment Data for Descartes-08 at MGFA Session. Cartesian Therapeutics shared additional retreatment data for its lead candidate Descartes-08 in patients with generalized myasthenia gravis. The results were presented at the MGFA scientific session of the 2026 AANEM annual meeting. This update adds to the company's clinical development information and may influence future regulatory discussions.